FDA approves Medtronic device for sealing off deeper, smaller brain aneurysms

Migraine headache/epilepsy brain image
The new indication includes small or medium aneurysms, through to the end of the brain's carotid artery. (CC0 Creative Commons)

Medtronic has received approval of an expanded indication from the FDA for its Pipeline Flex embolization device, for patients with smaller aneurysms found deeper in the brain.

The system was previously approved for endovascular treatment with large or giant, wide-necked intracranial aneurysms, located in the internal carotid artery from the petrous to the superior hypophyseal segments.

The new indication includes patients with small or medium brain aneurysms, from the petrous through to the terminus of the internal carotid artery, in parent blood vessels measuring between 2 mm and 5 mm in diameter.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The device is designed to divert blood away from an aneurysm, using a braided, cylindrical mesh tube implanted across the base of the aneurysm, to help reconstruct the damaged section of the blood vessel.

Medtronic's Pipeline Flex system

RELATED: Using genomics and machine learning to predict aneurysm risk

Its approval was based on a clinical study of 141 patients with an average aneurysm size of 5 millimeters. The study’s one-year occlusion rate reached 76.7%, with a 2.2% occurrence of major stroke or neurological death.

The device was originally approved after a five-year study of large or giant aneurysms, demonstrating efficacy rates from 70.8% at one year, to 95% after five years, with no documented cases of recurrence, according to Medtronic.

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.